F
FELIQS
Japan · Biotech
FELIQS develops small-molecule medicines for retinal diseases.
Product
FELIQS is a Japanese biotechnology company developing small-molecule medicines that target oxidized lipids. Its lead programme, FLQ-101, is being developed to prevent retinopathy of prematurity, an eye disease affecting premature infants.
Founded in Kurume in 2019, the company builds on research into lipid oxidation. It is advancing FLQ-101 through US clinical development and established a US headquarters in 2025.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A total including extension | $10M | Beyond Next Ventures, Inc. — LeadFFG Venture Business Partners, Inc. — ParticipantJapan Science and Technology Agency — ParticipantKeio Innovation Initiative — ParticipantMitsubishi UFJ Capital Co., Ltd. — Participant |